<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2164">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05132985</url>
  </required_header>
  <id_info>
    <org_study_id>NIC-0102</org_study_id>
    <nct_id>NCT05132985</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma</brief_title>
  <official_title>Neoadjuvant Icotinib With Chemotherapy for Resectable Stage II-IIIB N2 EGFR Mutation-positive Lung Adenocarcinoma: A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liaoning Tumor Hospital &amp; Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Icotinib is a first-generation inhibitor of EGFR-tyrosine kinase inhibitor in patients with&#xD;
      non-small-cell lung cancer (NSCLC). Here we will evaluate neoadjuvant Icotinib with&#xD;
      chemotherapy prior to surgery, in patients with resectable stage II-IIIB N2 EGFR&#xD;
      mutation-positive NSCLC. The primary endpoint is centrally assessed major pathological&#xD;
      response at the time of resection. Secondary endpoints include pathological complete&#xD;
      response, objective response rate, R0 resection rate at the time of resection, disease-free&#xD;
      survival, and overall survival. Safety and tolerability will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major pathological response(MPR)</measure>
    <time_frame>Up to approximately 30 months</time_frame>
    <description>Patients with tumors with ≤10% residual viable cancer cells (identified by routine hematoxylin and eosin staining) in the lung primary tumor after neoadjuvant treatment at the time of resection will be considered to have had an MPR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response (pCR)</measure>
    <time_frame>Up to approximately 30 months</time_frame>
    <description>Patients with no residual viable tumor cells in any of the specimens (primary tumors, lymph nodes and margins) will be considered to have had a pCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>Up to approximately 30 months</time_frame>
    <description>defined as the sum of the complete response plus partial response divided by the total number of included patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>Up to approximately 30 months</time_frame>
    <description>Free resection margins proved microscopically;Systematic nodal dissection in its wider form or, if it is not performed, lobe-specific systematic nodal dissection;There should be no extracapsular extension of tumor in nodes removed separately or those at the margin of the main lung specimen.&#xD;
;The highest mediastinal node that has been removed must be negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival(DFS)</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>DFS will be defined as the time from surgery until the first instance of disease recurrence (local or distant) or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>OS will be defined as the time from randomization until death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>NSCLC</condition>
  <condition>EGF-R Positive Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Icotinib+chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy (pemetrexed + carboplatin/cisplatin ) will start within 1-3 days from enrollment at 21-day (+/-3 days) intervals (Q3W) prior to surgery. Before surgery a tumor assessment will be done to exclude evidence of progression. Patients with radiographically stable disease or partial response may be considered for operation.&#xD;
Icotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of Icotinib is 125mg 1tt(Take 1 tablet 3 times a day) orally.&#xD;
Surgery: Surgery must be done within the 3rd to 4th week (+7 days) from day 21 cycle 2 of neoadjuvant treatment.&#xD;
Adjuvant treatment: Patients receive additional 2 cycles of platinum-based doublet chemotherapy(Researcher decide) on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icotinib</intervention_name>
    <description>125mg 1tt(Take 1 tablet 3 times a day) orally.</description>
    <arm_group_label>Icotinib+chemotherapy</arm_group_label>
    <other_name>Conmana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75 mg/m2 (IV，Q3W)</description>
    <arm_group_label>Icotinib+chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 5 (IV, Q3W)</description>
    <arm_group_label>Icotinib+chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500 mg/m2 (IV, Q3W)</description>
    <arm_group_label>Icotinib+chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Male or female, aged ≥18 years and ≤75 years&#xD;
&#xD;
          -  Histologically or cytologically documented lung adenocarcinoma with completely&#xD;
             resectable disease (Stage II-IIIB N2, according to the 8th edition of the IASLC&#xD;
             Staging Manual in Thoracic Oncology)&#xD;
&#xD;
          -  Complete surgical resection of the primary NSCLC must be deemed achievable, as&#xD;
             assessed by an MDT evaluation&#xD;
&#xD;
          -  A tumor which harbors either Ex19del or L858R EGFR-TKI-sensitizing mutations, either&#xD;
             alone&#xD;
&#xD;
          -  ECOG PS 0/1 at enrollment, with no deterioration over the previous 2 weeks prior to&#xD;
             baseline or day of first dosing&#xD;
&#xD;
          -  Adequate organ and marrow function as defined by:&#xD;
&#xD;
               -  Hemoglobin: ≥9.0 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count: ≥1.5 × 109/l&#xD;
&#xD;
               -  Platelet count: ≥100 × 109/l&#xD;
&#xD;
               -  Serum bilirubin: ≤1.5 ULN&#xD;
&#xD;
               -  ALT and AST: ≤2.5 × ULN&#xD;
&#xD;
               -  Creatinine clearance: ≥60 ml/min&#xD;
&#xD;
          -  Life expectancy of 6 months prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with systemic anti-cancer treatment for NSCLC, EGFR-TKI treatment or&#xD;
             pre-operative radiotherapy&#xD;
&#xD;
          -  EGFR-TKI-sensitizing mutations with T790M&#xD;
&#xD;
          -  Mixed small cell and non-small-cell lung cancer histology&#xD;
&#xD;
          -  T4 tumors infiltrating the aorta, esophagus and/or heart&#xD;
&#xD;
          -  Bulky N2 disease&#xD;
&#xD;
          -  Candidates for segmentectomies or wedge resections only&#xD;
&#xD;
          -  Medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid&#xD;
             treatment or any evidence of clinically active ILD&#xD;
&#xD;
          -  Severe or uncontrolled systemic diseases/active infections, history of allogeneic&#xD;
             organ transplantation, history of primary immunodeficiency, history of another primary&#xD;
             malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongxu Liu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liaoning Cancer Hospital &amp; Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongxu Liu, Doctor</last_name>
      <phone>18040097698</phone>
      <email>hxliu@cmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Huan Wang, Doctor</last_name>
      <phone>18941634184</phone>
      <email>dr.wanghuan.cmu@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014 May 3;383(9928):1561-71. doi: 10.1016/S0140-6736(13)62159-5. Epub 2014 Feb 25. Review.</citation>
    <PMID>24576776</PMID>
  </reference>
  <reference>
    <citation>Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol. 2008 Apr;73(4):1290-300. doi: 10.1124/mol.107.042382. Epub 2008 Jan 10.</citation>
    <PMID>18187583</PMID>
  </reference>
  <reference>
    <citation>La Monica S, Madeddu D, Tiseo M, Vivo V, Galetti M, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Falco A, Gervasi A, Lagrasta CA, Naldi N, Barocelli E, Ardizzoni A, Quaini F, Petronini PG, Alfieri R. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation. J Thorac Oncol. 2016 Jul;11(7):1051-63. doi: 10.1016/j.jtho.2016.03.006. Epub 2016 Mar 19.</citation>
    <PMID>27006151</PMID>
  </reference>
  <reference>
    <citation>Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. J Clin Oncol. 2016 Sep 20;34(27):3258-66. doi: 10.1200/JCO.2016.66.9218. Epub 2016 Aug 9.</citation>
    <PMID>27507876</PMID>
  </reference>
  <reference>
    <citation>Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol. 2020 Jan 10;38(2):115-123. doi: 10.1200/JCO.19.01488. Epub 2019 Nov 4.</citation>
    <PMID>31682542</PMID>
  </reference>
  <reference>
    <citation>Zhong WZ, Chen KN, Chen C, Gu CD, Wang J, Yang XN, Mao WM, Wang Q, Qiao GB, Cheng Y, Xu L, Wang CL, Chen MW, Kang X, Yan W, Yan HH, Liao RQ, Yang JJ, Zhang XC, Zhou Q, Wu YL. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. J Clin Oncol. 2019 Sep 1;37(25):2235-2245. doi: 10.1200/JCO.19.00075. Epub 2019 Jun 13.</citation>
    <PMID>31194613</PMID>
  </reference>
  <results_reference>
    <citation>Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016 Jan;11(1):39-51. doi: 10.1016/j.jtho.2015.09.009.</citation>
    <PMID>26762738</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 14, 2021</study_first_submitted>
  <study_first_submitted_qc>November 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 28, 2021</last_update_submitted>
  <last_update_submitted_qc>November 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Liaoning Tumor Hospital &amp; Institute</investigator_affiliation>
    <investigator_full_name>HongxuLiu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>NSCLC, EGFR, Icotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

